Drug dosing in continuous renal replacement therapy: general rules

被引:97
作者
Schetz, Miet [1 ]
机构
[1] Catholic Univ Louvain, Dept Intens Care Med, B-3000 Louvain, Belgium
关键词
acute kidney injury; continuous renal replacement therapy; drug elimination; pharmacodynamics; CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION; INTENSIVE-CARE-UNIT; HIGH-VOLUME HEMOFILTRATION; IN-VITRO; ANTIMICROBIAL THERAPY; PHARMACOKINETICS; MEROPENEM; FAILURE; ELIMINATION;
D O I
10.1097/MCC.0b013e3282f0a3d3
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose of review Continuous renal replacement therapy is increasingly used in the management of acute kidney injury in critically ill patients. The potential extracorporeal removal of drugs, in particular the removal of antimicrobials, is a concern to many clinicians. The results of clinical studies cannot be generalized because different treatment modalities and settings are used in heterogeneous patient populations. This review aims to provide general guidelines for drug dosing during continuous renal replacement therapy. Recent findings The basic principles underlying drug removal with different modalities of continuous renal replacement therapy are reviewed and general approaches for drug dosage adaptation are proposed. Dosing should consider extracorporeal clearance, mainly depending on the dose and mode of therapy, type of membrane and protein binding, but also fractional extracorporeal clearance, accounting for hepatic, metabolic and residual renal clearance. Of note, pharmacokinetic variables may be highly variable in the critically ill. Appropriate dosing of antimicrobials additionally requires the application of pharmacodynamic principles. For nontoxic antimicrobials, the clinician should prefer slight overdosing, while monitoring of plasma concentrations is crucial for drugs with a narrow therapeutic index. Summary Drug dosage adaptation during continuous renal replacement therapy can use several approaches, which all include a degree of unpredictability and thus require maximal reliance on drug monitoring.
引用
收藏
页码:645 / 651
页数:7
相关论文
共 54 条
[1]   Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore [J].
Ambrose, Paul G. ;
Bhavnani, Sujata M. ;
Rubino, Christopher M. ;
Louie, Arnold ;
Gumbo, Tawanda ;
Forrest, Alan ;
Drusano, George L. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) :79-86
[2]   Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous Venovenous Hemofiltration [J].
Arzuaga, A ;
Maynar, J ;
Gascón, AR ;
Isla, A ;
Corral, E ;
Fonseca, F ;
Sánchez-Izquierdo, JA ;
Rello, J ;
Canut, A ;
Pedraz, JL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (02) :168-176
[3]   Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration [J].
Bellmann, R ;
Egger, P ;
Gritsch, W ;
Bellmann-Weiler, R ;
Joannidis, M ;
Kaneider, N ;
Dunzendorfer, S ;
Wiedermann, CJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (03) :671-681
[4]   Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg [J].
Bergner, R ;
Hoffmann, M ;
Riedel, KD ;
Mikus, G ;
Henrich, DM ;
Haefeli, WE ;
Uppenkamp, M ;
Walter-Sack, I .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (04) :1019-1023
[5]   Pharmacokinetic changes in critical illness [J].
Boucher, Bradley A. ;
Wood, G. Christopher ;
Swanson, Joseph M. .
CRITICAL CARE CLINICS, 2006, 22 (02) :255-+
[6]   Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing [J].
Bouman, Catherine S. C. ;
Van Kan, Hendrikus J. M. ;
Koopmans, Richard P. ;
Korevaar, JohannaC. ;
Schultz, Marcus J. ;
Vroom, Margreeth B. .
INTENSIVE CARE MEDICINE, 2006, 32 (12) :2013-2019
[7]   Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates [J].
Brunet, S ;
Leblanc, M ;
Geadah, D ;
Parent, D ;
Courteau, S ;
Cardinal, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (03) :486-492
[8]   Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients [J].
Bugge, JF .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2001, 45 (08) :929-934
[9]   The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration - An in vitro study of levofloxacin [J].
Choi, G ;
Gomersall, CD ;
Lipman, J ;
Wong, A ;
Joynt, GM ;
Leung, P ;
Ramsay, SJ ;
Ho, OM .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (05) :468-472
[10]   Dose determinants in continuous renal replacement therapy [J].
Clark, WR ;
Turk, JE ;
Kraus, MA ;
Gao, DY .
ARTIFICIAL ORGANS, 2003, 27 (09) :815-820